DE69300158D1 - TGF-Beta induziertes Gen und Protein. - Google Patents

TGF-Beta induziertes Gen und Protein.

Info

Publication number
DE69300158D1
DE69300158D1 DE69300158T DE69300158T DE69300158D1 DE 69300158 D1 DE69300158 D1 DE 69300158D1 DE 69300158 T DE69300158 T DE 69300158T DE 69300158 T DE69300158 T DE 69300158T DE 69300158 D1 DE69300158 D1 DE 69300158D1
Authority
DE
Germany
Prior art keywords
tgf
protein
beta
gene
induced gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69300158T
Other languages
English (en)
Other versions
DE69300158T2 (de
Inventor
Anthony F Purchio
Michael G Neubauer
John E Skonier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of DE69300158D1 publication Critical patent/DE69300158D1/de
Application granted granted Critical
Publication of DE69300158T2 publication Critical patent/DE69300158T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69300158T 1992-02-05 1993-02-04 TGF-Beta induziertes Gen und Protein. Expired - Fee Related DE69300158T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83383592A 1992-02-05 1992-02-05

Publications (2)

Publication Number Publication Date
DE69300158D1 true DE69300158D1 (de) 1995-06-29
DE69300158T2 DE69300158T2 (de) 1995-10-19

Family

ID=25265395

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69300158T Expired - Fee Related DE69300158T2 (de) 1992-02-05 1993-02-04 TGF-Beta induziertes Gen und Protein.

Country Status (8)

Country Link
US (1) US5444164A (de)
EP (1) EP0555989B1 (de)
JP (1) JPH07133296A (de)
AT (1) ATE123060T1 (de)
CA (1) CA2088804A1 (de)
DE (1) DE69300158T2 (de)
DK (1) DK0555989T3 (de)
ES (1) ES2073327T3 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6306421B1 (en) 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6395494B1 (en) * 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US5770609A (en) 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US5595722A (en) 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6663881B2 (en) 1993-01-28 2003-12-16 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
DE69435137D1 (de) * 1993-05-13 2008-10-16 Poniard Pharmaceuticals Inc Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind
US5889159A (en) * 1993-10-29 1999-03-30 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies to tumor marker TC1 and methods for use of same
US5599788A (en) * 1994-07-01 1997-02-04 Advanced Tissue Sciences Method for accelerating skin wound healing with H3 protein
JPH11510479A (ja) 1995-06-07 1999-09-14 ネオルックス コーポレイション タモキシフェン類似体による心臓血管疾病の予防及び治療
US5981217A (en) * 1995-12-11 1999-11-09 Mayo Foundation For Medical Education And Research DNA encoding TGF-β inducible early factor-1 (TIEF-1), a gene expressed by osteoblasts
US6117911A (en) 1997-04-11 2000-09-12 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
US6218360B1 (en) * 1998-11-19 2001-04-17 The Schepens Eye Research Institute Collagen based biomaterials and methods of preparation and use
KR100388935B1 (ko) * 1999-10-18 2003-06-25 주식회사 리젠 바이오텍 재조합 βｉｇ-ｈ3 단백질 및 그 제조방법
KR100378949B1 (ko) * 2000-05-13 2003-04-08 주식회사 리젠 바이오텍 세포 부착, 확산 및 탈착 활성을 나타내는 펩타이드 및그의 유도체
KR100385293B1 (ko) * 2000-05-13 2003-05-23 주식회사 리젠 바이오텍 βｉｇ-ｈ3의 일부 도메인을 이용한 세포 부착 및 창상치유 방법
KR100382042B1 (ko) * 2000-05-13 2003-05-01 주식회사 리젠 바이오텍 창상 치료를 위한 βｉｇ-ｈ3 단백질 또는 그의 일부도메인을 포함하는 약학적 조성물
CA2410480A1 (en) * 2000-05-26 2001-12-06 Board Of Trustees Of The University Of Illinois Reagents and methods for identifying and modulating expression of genes regulated by retinoids
KR100609006B1 (ko) * 2001-04-19 2006-08-09 김인산 βｉｇ­ｈ３ 단백질의 정량방법 및 이를 이용한 진단킷트
US20030211141A1 (en) * 2001-12-11 2003-11-13 Lebaron Richard G. Genetic and protein manipulation of betaIG-H3 for the treatment and cure of muscular dystrophies
US20050164197A1 (en) * 2002-04-19 2005-07-28 In-San Kim Method for measuring the amount of betaig-h3 protein and diagnostic kit using the same
WO2004012758A1 (en) * 2002-07-26 2004-02-12 DeveloGen Aktiengesellschaft für entwicklungsbiologische Forschung Use of tgf beta ig-h3 for preventing and treating obesity, diabetes and/or metabolic syndrome
KR100489731B1 (ko) * 2002-10-02 2005-05-16 경북대학교 산학협력단 피브로넥틴 및 βｉｇ-ｈ3의 일부 도메인을 포함하는 재조합 단백질을 함유하는 창상치료, 세포부착, 이동 및 증식 촉진용 약학적 조성물
KR100481796B1 (ko) * 2002-10-02 2005-04-11 경북대학교 산학협력단 섬유아세포의 αｖβ5 인테그린과 특이적으로 결합하는βｉｇ-ｈ3 단백질 유래 펩타이드
KR100568755B1 (ko) * 2003-04-03 2006-04-07 주식회사 리젠 바이오텍 Ｙｈ 모티프를 포함하는 펩타이드를 유효성분으로함유하는 혈관신생 억제제
US20080274955A1 (en) * 2004-04-13 2008-11-06 Kyungpook National University Industry Academic Cooperation Foundation Novel Use of a Polypeptide Comprising Fas-1 Domain

Also Published As

Publication number Publication date
DK0555989T3 (da) 1995-07-24
EP0555989B1 (de) 1995-05-24
ES2073327T3 (es) 1995-08-01
CA2088804A1 (en) 1993-08-06
US5444164A (en) 1995-08-22
ATE123060T1 (de) 1995-06-15
JPH07133296A (ja) 1995-05-23
EP0555989A1 (de) 1993-08-18
DE69300158T2 (de) 1995-10-19

Similar Documents

Publication Publication Date Title
ATE123060T1 (de) Tgf-beta induziertes gen und protein.
ATE143811T1 (de) Herstellung und verwendung von il-6
DE3650751T2 (de) Antikörper gegen Saugetier-Interleukin-4 und Peptide verwendbar als Antigenen für deren Herstellung
FI831818A0 (fi) Mikrobiologiskt framstaellda - och -interferoner, dessa interferoner kodande dna-sekvenser, dennagenetiska information innehaollande mikroorganismer och deras framstaellningsfoerfarande
NO911688D0 (no) Neurotrophin-3, en ny neurotrofisk faktor relatert til neurovekstfaktor og hjerne-avledet neurotrofisk faktor.
ATE99737T1 (de) Tgf-beta codierende nucleinsaeure und deren verwendungen.
CA2066618A1 (en) Plasmids containing dna encoding the amino acid sequence of tcf-ii, transformed cells with the plasmids, and production method of biologically active substance using the transformed cells
ATE121776T1 (de) Expression des biologisch aktiven faktors xiii.
DK0666914T3 (da) Hidtil ukendt P-selectin-ligandprotein
DE3853023D1 (de) Produktion von Kallikrein.
NO177270C (no) Fremg. for fremstilling av terapeutisk aktive, humane granulocytt-makrofag-"kolonistimulerende"-faktorproteiner (GM-CSF), bakteriell ekspresjonvektor som er i stand til å uttrykke GM-CSF samt bakteriecelle inneholdende vektoren
ATE134219T1 (de) Menschliches mk gen und protein-sequenz
ATE339878T1 (de) Myc-bindende zinkfinger-proteine, ihre herstellung und ihre verwendung
ATE95564T1 (de) Aeusseres membranprotein f von pseudomonas aeruginosa.
DE3777367D1 (de) Hirudin-variante, deren verwendung und herstellung.
FI893681A0 (fi) N-2,3-butadienyltri- och tetra-aminoalkanderivat.
DE3881023D1 (de) Proteine, expressionsvektoren, die fuer solche proteine kodierende dna enthalten und zellen, die solche expressionsvektoren enthalten.
DK145988D0 (da) Genteknologisk fremstillet 140 kd-antigen af plasmodium falciparum og dettes anvendelse
ATE145939T1 (de) Mitogen für die glatte muskulatur und dessen kodierende dns
RU93058612A (ru) Клонирование и экспрессия автоантигенов декарбоксилазы глутаминовой кислоты островковых клеток человека

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee